WBB Securities upgraded shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a speculative buy rating to a buy rating in a report issued on Thursday, MarketBeat Ratings reports. WBB Securities currently has $7.00 price target on the biopharmaceutical company’s stock.

Several other research firms have also commented on TTPH. HC Wainwright reiterated a buy rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, July 16th. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, August 16th. ValuEngine lowered Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, July 30th. B. Riley lifted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a buy rating in a research report on Tuesday, August 28th. Finally, Needham & Company LLC reiterated a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has an average rating of Hold and an average price target of $6.41.

TTPH traded down $0.07 on Thursday, hitting $3.24. The company had a trading volume of 18,697 shares, compared to its average volume of 1,250,425. The firm has a market cap of $170.73 million, a P/E ratio of -1.26 and a beta of 2.65. Tetraphase Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $7.98.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.18. The company had revenue of $11.58 million during the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. analysts predict that Tetraphase Pharmaceuticals will post -1.38 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Flagship Harbor Advisors LLC purchased a new position in shares of Tetraphase Pharmaceuticals during the second quarter valued at approximately $104,000. Cubist Systematic Strategies LLC boosted its position in shares of Tetraphase Pharmaceuticals by 232.1% during the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 24,837 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Tetraphase Pharmaceuticals during the second quarter valued at approximately $179,000. Dynamic Technology Lab Private Ltd boosted its position in shares of Tetraphase Pharmaceuticals by 322.1% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 58,079 shares during the period. Finally, Alambic Investment Management L.P. purchased a new position in shares of Tetraphase Pharmaceuticals during the first quarter valued at approximately $356,000. Institutional investors and hedge funds own 40.94% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Further Reading: Understanding Stock Ratings

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.